Aerovit

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aerovit

Property Description
Active ingredient Salbutamol (INN)
Form Pressurized metered-dose inhaler, Nebuliser solution
Pharmacological class Short-Acting Beta-2 Agonist (SABA)
Common use Acute relief of bronchospasm
Origin Synthetic compound

Aerovit is a prescription-only medicine whose active ingredient is Salbutamol (or Salbutamol sulfate). This substance is categorized within the pharmacological class of Short-Acting Beta-2 Agonists (SABA). This classification is a key functional identifier for the medicine and reflects its mechanism of action.

The International Nonproprietary Name (INN) for the active component is Salbutamol. As a synthetic compound that functions as a single active ingredient product, its design specifically targets receptors in the lungs responsible for controlling airway muscle tension.


Forms, Action, and General Purpose

Aerovit is most commonly delivered via inhalation using a pressurized metered-dose inhaler (Aerosol), or as a liquid nebuliser solution for use with a respirator device. Its general therapeutic purpose is to provide fast relief from the sudden, acute tightening of the airways, technically termed bronchospasm, which is characterized by its ability to swiftly restore airflow during an episode.

By relaxing the smooth muscles surrounding the bronchi, Aerovit quickly reverses airway constriction. Its primary role is the rapid treatment of bronchospasm. The medication is used to promptly ease difficulty breathing when airways suddenly narrow.


What Makes Aerovit a Short-Acting "Reliever"?

Aerovit is characterized as a short-acting medicine because its therapeutic effect on the airways is achieved rapidly—typically within minutes—and its duration of action is constrained, usually lasting between three and six hours. This rapid-onset, limited-duration profile dictates its functional role as a "reliever" medication.

This feature means that Aerovit is specifically intended for as-needed use to address acute symptoms, which is a differentiating factor from maintenance therapies. Salbutamol's action is rapid and of short duration, designed to provide quick but temporary opening of the airways.

What side effects are possible with Aerovit?

Possible Side Effects and Safety Information

The safety profile of Aerovit (Salbutamol) is based on frequency classifications and system-organ classes documented in official regulatory sources, such as the FDA and EMA prescribing information. These documents establish the medicine's potential adverse reactions and safety constraints.

Commonly Documented Adverse Reactions

The most frequently classified reactions, which are generally associated with the short-acting beta-2 agonist (SABA) class, often affect the nervous system and cardiovascular system. These include tremor (classified as very common), headache, tachycardia (increased heart rate), and palpitations (all classified as common in official labels). Other common reactions include muscle cramps.

Rare and Serious Adverse Reactions

Official labels also detail rare but clinically significant reactions. These include severe hypersensitivity reactions (such as angioedema or hypotension), which are documented as very rare. A critical, rare reaction is paradoxical bronchospasm, an unexpected, immediate tightening of the airways following administration. Other rare effects include cardiac arrhythmias and a potentially serious reduction in blood potassium levels, known as hypokalemia, often seen with high-dose use.

Safety Considerations and Limitations

Regulatory documents advise caution when using Aerovit in individuals with pre-existing conditions like severe cardiac disorders (e.g., ischaemic heart disease), hypertension, diabetes mellitus, or hyperthyroidism, due to the drug's systemic effects. Furthermore, the official prescribing information generally restricts concomitant use with non-selective beta-blockers, such as propranolol, due to safety concerns and potential antagonism of effects. Hyperactivity has been reported in children as a very rare effect.

Overdose and Emergency Response

Aerovit Overdose and when to seek help

The regulatory documentation for Aerovit (Salbutamol) defines overdose through a cluster of specific physiological and clinical findings, classifying it as a situation carrying the potential for fatal outcomes.


Overdose Scope

  • Documented overdose presentations: Manifestations frequently affect the Cardiovascular System (tachycardia, cardiac arrhythmias, chest pain) and Metabolic/Electrolyte Balance. Documented physiological changes include Hypokalemia (low serum potassium), Hyperglycemia, and Lactic Acidosis. Systemic signs documented are tremors, agitation, and seizures (convulsions).
  • Emergency-response statements: Immediate medical attention must be sought upon suspicion of overdose, and also when the severe outcome of paradoxical bronchospasm occurs. Urgent help is required even if symptoms are not immediately apparent or felt.

Overdose Classifications

  • Severity classification (as defined in official documents): Overdose is classified as a serious acute event associated with the risk of complications, including potential cardiac ischemia.
  • Supportive Management: Management is primarily symptomatic and supportive, detailing specific interventions such as the use of beta-blockers for cardiac effects, potassium supplementation for metabolic derangements, and hospital monitoring to observe cardiorespiratory status.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with severe cardiovascular and metabolic manifestations that require specific intervention.
  • Seek emergency medical attention immediately, as excessive use is associated with fatal risk.
  • No specific single antidote is listed; management relies on officially described supportive care procedures.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile through the presence of severe cardiovascular and metabolic adverse events that necessitate specific, documented supportive care. The official emergency-seeking condition is mandated—seeking immediate medical attention—which is directly tied to the potential for serious complications, thus requiring rapid clinical evaluation and continuous observation of the documented physiological changes.

Therapeutic Uses of Aerovit

What Aerovit Treats: Main Uses and Benefits


Aerovit is primarily used across domains where short-term symptom management is appropriate, helping address symptom clusters that create noticeable functional strain. For instance, it is commonly used for managing symptoms related to physical discomfort, systemic imbalance, or heightened physiological activity in conditions characterized by periods of heightened symptoms or episodic manifestations. Medicines in this category are relevant when supportive symptom management is needed.

The medicine is applied in scenarios where additional management of discomfort is required, such as during phases of increased distress or discomfort. The support provided helps ease the overall symptom burden and may assist with supporting functional stability when symptoms interfere with routine activities.

“It supports the patient during difficult episodes by easing distress.”

This approach contributes to improved day-to-day comfort during symptomatic periods, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Sudden Symptom Intensification

Eligibility and Restrictions for Use

Official Eligibility Profile

The eligibility for using Aerovit (Salbutamol) is strictly defined by regulatory documents, classifying populations into permitted, restricted, or explicitly contraindicated groups.

Contraindications and Absolute Restrictions

Aerovit is contraindicated in patients with a history of hypersensitivity or allergic reaction to Salbutamol or any other component in the specific formulation. Furthermore, non-intravenous formulations of this medicine, such as the inhaler or nebulizer solution, must not be used to arrest uncomplicated premature labour or threatened abortion (tocolysis).

Age and Comorbidity-Based Use

Use is established for adults and adolescents and children aged 4 years and older. Safety and effectiveness are not established for children younger than 4 years of age. Caution is required for patients with severe cardiovascular disorders, thyrotoxicosis (overactive thyroid), or diabetes mellitus.

Pregnancy and Lactation

Use during pregnancy should only be considered if the expected benefit outweighs the possible risk to the fetus, as safety has not been established by controlled trials. Use while breastfeeding is not recommended unless essential, as the active substance is probably secreted in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Aerovit’s official interaction profile is defined by effects on the cardiovascular system and systemic electrolyte balance. The most significant restriction involves Non-selective Beta-blocking drugs, such as Propranolol, which are not usually prescribed together due to pharmacodynamic antagonism that may induce severe bronchospasm. This constitutes a formal regulatory restriction.

Co-administration with Xanthine Derivatives, Glucocorticoids (Steroids), or certain Diuretics may potentiate the risk of clinically significant hypokalaemia (low serum potassium). This electrolyte imbalance risk is officially noted as being further potentiated in patients with acute severe asthma or hypoxia. Additionally, Corticosteroids can exaggerate the increase in blood glucose levels caused by Aerovit in diabetic patients.

Specific caution is advised with Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs), as these may potentiate the vascular effects of Aerovit. Furthermore, Aerovit may decrease serum Digoxin levels, and the hypokalaemia risk increases the chance of arrhythmias in patients on Digoxin. A procedural constraint exists for co-administration with Nebulised Anticholinergics, which requires careful administration to prevent mist from entering the eyes due to the reported risk of acute angle-closure glaucoma.

This profile summarizes the official regulatory constraints on co-administration, focusing strictly on the resulting physiological and concentration changes as documented in prescribing information.

Mechanism of Action

Selective beta2-Adrenergic Receptor Engagement

The drug's mechanism initiates by acting as an agonist at the beta2-adrenergic receptors (beta2-ARs), which are highly expressed on bronchial smooth muscle cells. This targeted interaction begins an intracellular signaling cascade within the smooth muscle cell, operating within autonomic pathways.

️ Modulating the Contraction-Relaxation Cascade

Receptor activation stimulates a Gs protein, leading to an increase of the second messenger cAMP. The elevated cAMP levels activate Protein Kinase A (PKA), which functionally inhibits the enzyme Myosin Light Chain Kinase (MLCK) and reduces intracellular calcium ions (Ca^2+). This molecular sequence inhibits the formation of cross-bridges necessary for muscle shortening.

️ Resulting Physiological Consequence

By disrupting the contractile process, this mechanism causes the smooth muscles surrounding the bronchi to relax. This bronchial smooth muscle relaxation is the immediate physiological change that reverses the constriction of the air passages, leading to the widening of the airway lumen (bronchodilation). The resultant physiological change occurs with characteristic fast onset. The mechanism is subject to limitation by receptor desensitization with overuse or in cases where airway obstruction is due to non-muscular factors.

Dosage and Administration Information

How to Use Aerovit

Aerovit, which contains Salbutamol, is an inhaled medicine intended for as-needed use. The medicine is primarily delivered via oral inhalation through a pressurized Metered-Dose Inhaler (MDI) or as a nebuliser solution.


Official Dosing and Schedule

Usage patterns dictate that the medicine is administered on an as-needed (PRN) basis for acute symptom relief. Standard adult dosing for acute bronchospasm relief is typically 1 to 2 inhalations (90 mcg or 100 mcg per puff), which may be repeated every 4 to 6 hours, as required by symptoms. For the prophylactic management of exercise-induced bronchospasm, the dose is 2 inhalations taken 15 to 30 minutes before physical activity. There is a general clinical boundary for routine PRN use, where the total daily usage should not exceed 8 inhalations in a 24-hour period.


Administration Requirements

For proper delivery, the MDI canister must be shaken well immediately before each actuation. If the inhaler is new or has been unused for a specified number of days, priming (releasing a few test sprays) is required to ensure the correct dose is delivered. Administration for all forms is by oral inhalation only. For the nebuliser solution, the dose is administered using a suitable nebuliser device, and the solution must not be injected or swallowed. Pediatric administration in younger children may require the concurrent use of a spacer device to ensure successful delivery of the medicine to the lungs. The inhaler's mouthpiece must be periodically cleaned with warm water to prevent dose delivery obstruction.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aerovit

The research base for Aerovit (Salbutamol) is extensive, relying on numerous short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been used in research exploring how symptoms change over time during sudden episodes of breathing difficulty, such as acute exacerbations related to asthma or Chronic Obstructive Pulmonary Disease (COPD).

Evidence for Use in Acute Bronchospasm

The research frequently examined objective measures of lung function, including the Forced Expiratory Volume in 1 second (FEV1 ), following administration. In acute care settings, studies focusing on episodes where symptoms become more noticeable report how symptoms evolved in the observed populations. Findings describe patterns observed in the studies related to change in physiological markers (FEV1 and PEFR) following administration.

However, follow-up durations in these acute studies were generally limited, often focusing only on the first few hours. The evidence provides insight into short-term changes, but long-term outcomes are not fully established by this research.

Evidence for Preventing Exercise-Induced Bronchospasm (EIB)

Research exploring the prevention of EIB typically involved specialized cross-over RCTs. These studies examined how symptoms related to physical discomfort were affected when Aerovit was administered before a standardized exercise challenge. Findings from these trials describe patterns related to lung function measurements compared to control groups immediately following the exercise period. Studies reported the duration of effect as short, with physiological measurements returning to baseline within a few hours.

Uncertainty and Research Gaps

Despite the high volume of short-term RCT data, certainty remains low in several key areas. The most significant gap is the lack of research exploring the long-term clinical consequences of frequent use, particularly when the drug is used without concurrent maintenance treatment. Data for older adults also remain insufficient in comparison to the extensive data available for younger individuals in the acute setting.

Key Studies & References

  1. BTS/NICE/SIGN Joint Guideline on Asthma: diagnosis, monitoring and chronic asthma management
  2. Salbutamol in the Management of Asthma: A Review

Frequently Asked Questions (FAQ)

Common questions about Aerovit (FAQ)


Q: How long does it typically take to notice the effects of Aerovit?

Regulatory documents indicate that the onset of action for Aerovit is fast, consistent with its purpose as a quick-acting reliever medicine.

The initial therapeutic effects are generally observed within 5 minutes following administration.


Q: Is it normal to feel a bit nauseous when first starting Aerovit?

Nausea has been documented in official adverse reaction reports as a possible side effect that some patients may experience.

It is listed in the official safety profile, although it is not typically among the most frequently reported effects.


Q: Can Aerovit be taken with common over-the-counter pain relievers?

Regulatory documents detailing the drug’s interaction profile focus on specific classes of prescription drugs such as beta-blockers and certain antidepressants.

Official labels do not typically detail specific warnings or cautions related to common non-prescription pain relievers in their drug interaction profiles.


Q: Is Aerovit considered safe for long-term use?

Aerovit is officially intended for as-needed, short-term use to relieve acute symptoms.

The medicine’s warnings describe that increased frequency of use, particularly without concurrent anti-inflammatory therapy, may be an indication of worsening underlying disease control.


Q: What should I do if I miss a dose of Aerovit (general clarification)?

Aerovit is an as-needed medicine for symptom relief, not a scheduled drug.

Official guidance indicates that if a patient is symptom-free, they should not attempt to compensate for any perceived missed use by taking additional doses.


Q: Does Aerovit have a risk of dependence or withdrawal symptoms?

Regulatory documents do not typically list dependence as a common risk or safety concern associated with Aerovit.

However, official information cautions against increasing the frequency of use without medical consultation, as this increase may signal worsening disease control.


Q: Are there any known food or drink restrictions while using Aerovit?

Official drug interaction profiles and patient consumer information for Aerovit do not list any specific food or drink restrictions.

As the medicine is delivered by inhalation directly to the lungs, its action is generally not dependent on what is consumed.


Q: Why does the official document mention a risk of [rare side effect]? (Seeking clarification)

Official regulatory documents mention all adverse reactions that were either reported during clinical trials or identified through post-market surveillance.

This comprehensive reporting is a safety measure to ensure that patients and prescribers are fully informed of the drug’s potential safety profile, even for effects that are classified as very rare.


Q: Can older adults use Aerovit, and is there a specific caution for them?

Aerovit is approved for use in adults, including older individuals.

Official caution is advised because older adults are more likely to have age-related cardiac, kidney, or liver issues. These conditions may require careful consideration of the dose.


Q: Does Aerovit need to be stopped gradually, or can it be stopped right away?

Regulatory guidance states that Aerovit and other asthma medications should not be discontinued without the involvement of a healthcare professional.

Stopping treatment unexpectedly may lead to a worsening of the underlying breathing condition.


Q: Do children or teenagers have different side effects from Aerovit than adults?

The common side effects of Aerovit, such as tremor (shakiness) and headache, are generally observed across both adult and pediatric populations.

For children, official labels specifically note that hyperactivity is a reported adverse effect, although it is classified as very rare.


Q: How long does Aerovit stay in your system after the last dose?

The drug's half-life—the time it takes for half of the medicine to be cleared from the bloodstream—is generally described as being between 4 and 6 hours.

Based on official pharmacokinetic data, most of the administered dose is typically eliminated from the body within 72 hours.


Q: Are there any reports of Aerovit affecting mood or behavior?

Official prescribing information documents side effects that can affect the nervous system.

These include physical symptoms like headache and tremor (shakiness), and, particularly in children, hyperactivity has been reported as a very rare effect.


Q: What happens if I accidentally take two doses of Aerovit close together?

Official information indicates that the total daily usage is typically limited to a specific number of inhalations in a 24-hour period.

Use beyond this limit or taking doses too close together may increase the likelihood of side effects being experienced, which are documented in the safety profile.


Q: What kind of research evidence supports the use of Aerovit?

The evidence supporting the approval and use of Aerovit primarily comes from short-term Randomized Controlled Trials (RCTs).

These studies confirm that the medicine produces a measurable, immediate improvement in lung function during acute episodes of bronchospasm.


Q: Can Aerovit be split or crushed, or must it be swallowed whole?

Aerovit is an oral inhalation-only medicine administered using a pressurized metered-dose inhaler or as a nebulizer solution.

It is not intended to be modified, split, crushed, or swallowed whole.


Q: Is it necessary to take Aerovit at the same time every day?

No. Aerovit is classified as a short-acting agent and is specifically intended for as-needed (PRN) use.

It is generally administered only when symptoms, such as shortness of breath or wheezing, occur, or prior to exercise if treating exercise-induced bronchospasm.


Q: Is Aerovit known to cause problems with eyesight or hearing?

Official labels advise caution regarding eyesight only when Aerovit is co-administered with nebulized anticholinergics due to a reported risk of acute angle-closure glaucoma.

There is no general warning in official documents for the medicine causing problems with hearing.


Q: Are there any warnings about driving or operating machinery while on Aerovit?

Official patient information notes that if side effects such as dizziness, nervousness, or tremor are experienced, patients should refrain from activities requiring mental alertness and coordination, such as driving or operating machinery.

These activities should be postponed until these effects have passed.


Q: Is Aerovit ever used in combination with other major medications for the same condition?

Yes. Aerovit is a reliever medicine that is often used in combination with controller or maintenance therapies for underlying conditions like persistent asthma.

It is commonly used alongside inhaled corticosteroids (ICS), which are long-term treatments, to manage symptoms.


Q: What are the long-term safety profile concerns described in official documents?

Official documents highlight a key safety concern: the risk that the frequent or excessive use of Aerovit may mask a worsening of the underlying condition.

The warnings relate to the danger of relying on the reliever too heavily instead of using concurrent long-term controller medication.


Q: Can Aerovit be taken on an empty stomach or must it be taken with food?

Aerovit is an inhaled medicine, and the official instructions for use are focused on the administration technique for the inhaler or nebulizer.

Official prescribing information does not specify a requirement to take it with or without food.

How should Aerovit be stored and disposed of?

The storage and disposal of Aerovit must strictly comply with official regulatory guidelines to maintain its efficacy and ensure safety.

Storage Conditions

Requirement Official Instruction
Temperature Range Do not store above 25mathrmC or 30mathrmC and do not freeze or refrigerate the pressurized inhaler. The container must not be exposed to temperatures over 50mathrmC.
Protection The product must be protected from light. Nebuliser solution vials should be kept in the original foil over-wrap to maintain stability.
Child Safety Keep out of sight and reach of children to prevent accidental ingestion.

Handling and Disposal

Item Official Instruction
Container Safety The metal canister must not be punctured, broken, or burnt, even when empty.
Disposal Dispose of unused or expired product in accordance with local regulatory requirements. Due to propellant gases, used inhalers should be returned to a pharmacy for safe environmental disposal rather than being placed in household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aerovit found in:

A-Z Index: